ArticleCell reports2026
A Fkh1/2 binding site array in the WHI5 promoter drives sub-scaling transcription.
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A transcription-driven model of scaled myonuclear accretion reveals a quantitative role for nuclear reserve capacity.The Journal of physiology · 2026Article
Corrections and comments
- Update of
Authors and funding
11 authors.
Funding
Abstract
Cells maintain size homeostasis by coupling growth to division. In budding yeast, newborn cells contain similar amounts of the G1/S inhibitor Whi5, which is diluted as cells grow in G1 to promote cell cycle entry. Similar Whi5 amounts at birth arise from size-independent (sub-scaling) WHI5 mRNA production during S/G2/M and equal partitioning of Whi5 at division. Although chromatin association explains equal partitioning at division, the basis of sub-scaling transcription remained unclear. By systematically mutating the WHI5 promoter, we identify a core region from -126 to -75 bp upstream of the start codon that is responsible for sub-scaling. This sequence contains a repeating array of binding sites for the Fkh1/2 transcription factor. Mutating these sites, deleting FKH1 or FKH2, or disrupting Fkh1/2 dimerization weakens WHI5 sub-scaling. Together with structural predictions and a mathematical model of cooperative Fkh binding, our results suggest that sub-scaling WHI5 transcription is regulated by a Fkh1/2 heteropolymer that binds an array of sites in its core promoter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.